Trademark law governs more than just logo placement, it defines the legal boundaries of brand recognition and product integrity. A recent ruling by the U.S. Court of Appeals for the Fourth Circuit demonstrates how parallel imports - genuine goods sourced from foreign markets without authorization - can trigger significant liability under the Lanham Act. For organizations managing complex supply chains, this decision emphasizes the necessity of rigorous trademark monitoring and clarifies the limitations of the "genuine goods" defense.
The Material Differences Doctrine in Pharmaceutical Imports
The litigation centered on Gilead Sciences’ HIV medication, Biktarvy. A patient received a Turkish version of the drug through an alternative funding program facilitated by Rx Valet LLC and other intermediaries. This channel bypassed the domestic pharmacy network managed by Meritain Health and ProAct. Gilead initiated legal action, alleging trademark infringement and unfair competition.
The Fourth Circuit upheld a preliminary injunction prohibiting these entities from importing or facilitating the importation of the medication. The court’s decision relied on the "material differences doctrine." Under this principle, goods are not considered "genuine" if they differ materially from those authorized for sale in the domestic market, even when their chemical composition is identical.
In this instance, the Turkish-labeled packaging omitted several critical elements present on U.S. versions:
- The "Rx only" symbol
- The National Drug Code number
- Specific storage instructions
- A black box warning regarding Hepatitis B risk
The court applied a low threshold for materiality, noting that any slight difference relevant to consumers supports a finding of likelihood of confusion. Consequently, the absence of these warnings and identifiers meant the products were not genuine under the Lanham Act, regardless of their pharmacological equivalence.
Quality Control and Trademark Integrity
Beyond labeling issues, the quality-control doctrine played a pivotal role. Gilead demonstrated that the internationally sourced medications bypassed its established safety protocols, including temperature monitoring, traceability systems, and recall procedures. By removing the product from these safeguards, the importers severed the link between the manufacturer and the consumer.
This separation is critical for trademark claims involving genuine goods. Trademarks function not only as brand identifiers but as guarantees of quality and origin. When a third party intervenes in a way that prevents the trademark owner from maintaining control over the product’s presentation and safety, the trademark’s integrity is compromised. The court found that either the labeling discrepancies or the lack of quality control alone would have supported Gilead’s case, together, they established an "especially strong" likelihood of confusion.
Contributory Liability for Third-Party Service Providers
A significant aspect of this ruling concerns the liability of service providers like Meritain and ProAct. These entities argued that under Inwood Laboratories, Inc. v. Ives Laboratories, Inc., they could only be held liable for contributory infringement if they had prior notice of specific infringing acts. The Fourth Circuit rejected this narrow interpretation.
The court clarified that a defendant may be held liable if it continues to supply services to parties it knows or has reason to know are engaging in infringement. Formal notice is not required, constructive knowledge suffices. Internal communications revealed that Meritain employees were aware of the international sourcing and its implications but continued to process payments for these invoices as a "client service." Similarly, ProAct’s president acknowledged the labeling differences between the domestic and foreign versions.
This precedent limits the protection available to intermediaries who disregard potential infringement in pursuit of cost savings or operational efficiency. If a service provider has reason to suspect its clients are facilitating trademark infringement, continuing those services creates substantial legal exposure.
Strategic Implications for Business Monitoring
For businesses, particularly in healthcare, pharmaceuticals, and luxury goods, this case offers three vital lessons:
- Vigilance Over Assumptions: Assuming imported goods are "genuine" because they are chemically identical is a dangerous legal fallacy. Differences in packaging, labeling, or regulatory compliance can constitute material differences that trigger liability.
- Active Monitoring of Supply Chains: Companies must monitor their distribution networks, including third-party administrators and alternative funding programs. Passive ignorance is not a defense if evidence shows the company "had reason to know" of infringing activities.
- Documentation of Compliance: Internal records can be used as evidence of constructive knowledge. Employees who flag potential issues but are ignored by management expose the organization to greater risk. Robust internal reporting and compliance protocols are essential to demonstrate good faith and mitigate liability.
The Fourth Circuit’s decision reinforces that trademark protection is not limited to preventing counterfeits, it extends to controlling how authorized goods are presented and distributed within a market. As global trade expands, the distinction between genuine imports and infringing parallel trades remains a complex area of law. Businesses must prioritize proactive trademark monitoring and clear contractual safeguards to navigate these risks effectively.